Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Ritobegron in Spinal Cord Injury Patients
NCT02259751Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in neurogenic detrusor overactivity (NDO) comparing KUC 7483 CL with Placebo (2 arms). Primary endpoint: Change from baseline in volume at first contraction. Started Feb 2004; status: completed.
02
Drugs
ritobegron
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT02259751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259751.